By Evelyne Newton, Business Development Europe at Velocity Clinical Research Next week I will join industry leaders to explore one of the most pressing questions facing sites across Europe: how can clinical trial sites diversify therapeutic areas sustainably without compromising quality? In a competitive and fast-moving environment, diversification is often framed as a necessary growth … Read more
By Andrew Reina, Chief Revenue Officer Clinical research is at an inflection point. Sponsors and CROs are being asked to deliver trials that start faster, enrol more predictably, and generate data that stands up to increasing regulatory and commercial scrutiny. In that environment, long-standing approaches to site selection, which are often shaped by reputation, relationships, … Read more
When you first meet Fritz Raiser, DO, you could be forgiven for thinking he was on holiday. There’s a quiet ease about him, a calm confidence that feels almost out of place for someone who spends half his week in a busy emergency room and his days leading clinical trials. Warm and approachable, Dr. Raiser … Read more
A research career wasn’t part of Gerald Cephas, MD’s original plan. He trained in general surgery, intending to specialize in pediatrics, but a health setback during residency changed his course. “Toward the end of residency, I got sick,” he explains. “So, long story short, research presented itself as a Plan B, and I’ve been on … Read more
The loss of lean muscle mass has long been a concern for patients using GLP-1 therapies. New results from the Regeneron Phase 2 COURAGE trial, led by Julio Rosenstock, MD, at Velocity’s site in Dallas, TX, point to a potential solution. The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean … Read more
It’s a cliché at this point to say AI (artificial intelligence) is the future; there are people still struggling to work their smartphones who could tell you that. AI tools are too capable, and the commercial advantage too significant, for them not to become a sizeable part of our work and personal lives. But the … Read more
By Stephanie Anderson, Chief of Staff Representation in clinical trials is crucial for equitable healthcare. Yet, the nature of clinical trial sites, which have historically been based in municipal centers where patient populations are highest, automatically excludes huge swathes of the population, such as those living in rural areas. These sites are also rarely positioned … Read more
At Velocity Clinical Research, we’re proud to be one of the largest clinical trial patient networks in the world, with access to over one million patients in our database across more than 70 integrated sites. That scale puts us in a unique position to listen, learn, and lead—and it’s why we’re excited to share insights … Read more
When Velocity Clinical Research launched in December 2017, it had just two sites. Owned sites (SMOs) were the prevalent model at the time, and site networks were a collection of independent sites with a single point of contact. Velocity offered an alternative – a wholly owned and fully integrated network of clinical trial sites. That … Read more
Paul Evans was featured in Applied Clinical Trials‘ latest article weighing in on the real-world implications of recent executive orders affecting DEI initiatives nationwide. In the piece, Paul underscores Velocity’s unwavering commitment to inclusive, patient-centered research environments, stating: “Velocity believes that clinical trials should be a safe space for the entire LGBT community… It’s important … Read more